Executive Summary
Performant Recovery, Inc. (Performant Financial Corp.) locked in $124.2M CMS obligation for Medicare recovery auditing, with 64% ($79.8M) outlayed, signaling strong multi-year revenue visibility through 2027 (potential 2029). $41M in options offer upside amid full competition win. Fixed-price structure flags margin risks; monitor funding release on remaining $44.4M.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior All HHS Contracts digest from February 25, 2026.
Investment Signals (1)
- $124M CMS Medicare Recovery Contract (HIGH)▲
Firm fixed-price delivery order provides committed revenue through 2027 with 64% outlayed; options add $41M potential.
Risk Flags (2)
- Execution [MEDIUM RISK]▼
Firm fixed-price terms risk margin compression if costs exceed fixed payments.
- Market [MEDIUM RISK]▼
Extended term to 2029 exposes to HHS budget shifts; only 64% of obligation outlayed.
Opportunities (1)
- ◆
$41M in unexercised options plus potential 2-year extension to 2029.
Sector Themes (1)
- ◆
Large CMS commitment to commercial repayment center via open competition underscores demand for specialized recovery services.
Watch List (2)
- 👁
{"entity"=>"Performant Financial Corporation", "reason"=>"Dominates single-record period with $124M HHS exposure; 36% obligation pending outlay.", "trigger"=>"Outlay acceleration >$10M/quarter or option exercise"}
- 👁
{"entity"=>"CMS MSP CRC Funding", "reason"=>"$44.4M remaining obligation at risk of delay.", "trigger"=>"Budget cuts or performance disputes"}
Get daily alerts with 1 investment signals, 2 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: All HHS Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
US Pre-Market SEC Filings Roundup — May 26, 2026
US Pre-Market SEC Filings Roundup
May 26, 2026
Biotech Small-Cap Approvals — May 26, 2026
Biotech Small-Cap Approvals
May 26, 2026
Big Pharma Approvals — May 26, 2026
Big Pharma Approvals